Omeros’ OMS721 Receives FDA’s ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

 Omeros’ OMS721 Receives FDA’s ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Omeros’ OMS721 Receives FDA’s ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Shots:

  • The ODD is based on Omeros’ P-III program assessing OMS721 in patients with HSCT-TMA. Additionally, OMS721 is being evaluated in ongoing P-III program for IgA nephropathy, and aHUS respectively
  • With the above designation OMS721 will serve in both prevention and treatment of HSCT-TMA in EU and the US. OMS721 also received ODD in IgA nephropathy, and aHUS, BT for IgA nephropathy & FTD for aHUS
  • Omeros’ OMS721 is a mAb targeting MASP-2 while, holding WW rights for MASP-2 and all therapeutics targeting MASP-2 & developing small molecules for it. OMS721 also identified MASP-3 (for converting pro-factor D to factor D)

Click here to read full press release/ article | Ref: Omeros | Image: The Business Journals

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post